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Prostate cancerLoss of IQGAP2 contributes to the tumorigenesis of hepatocellular carcinoma and gastric cancer. However,
whether IQGAP2 also suppresses prostate tumorigenesis remains unclear. We report here that IQGAP2 is a
candidate tumour suppressor of prostate cancer (PC). Elevated IQGAP2 was detected in prostatic intraepithe-
lial neoplasia (PIN), early stages of PCs (Gleason score ≤3), and androgen-dependent LNCaP PC cells. Howev-
er, IQGAP2 was expressed at substantially reduced levels not only in prostate glands and non-tumorigenic
BPH-1 prostate epithelial cells but also in advanced (Gleason score 4 or 5) and androgen-independent PCs.
Furthermore, xenograft tumours that were derived from stem-like DU145 cells displayed advanced features
and lower levels of IQGAP2 in comparison to xenograft tumours that were produced from non stem-like
DU145 cells. Collectively, these results suggest that IQGAP2 functions in the surveillance of prostate tumori-
genesis. Consistent with this concept, ectopic IQGAP2 reduced the proliferation of DU145, PC3, and 293 T cells
as well as the invasion ability of DU145 cells. While ectopic IQGAP2 up-regulated E-cadherin in DU145 and
PC3 cells, knockdown of IQGAP2 reduced E-cadherin expression. In primary PC and DU145 cells-derived xe-
nograft tumours, the majority of tumours with high levels of IQGAP2 were strongly-positive for E-cadherin.
Therefore, IQGAP2 may suppress PC tumorigenesis, at least in part, by up-regulation of E-cadherin. Mechanis-
tically, overexpression of IQGAP2 signiﬁcantly reduced AKT activation in DU145 cells and inhibition of AKT
activation upregulated E-cadherin, suggesting that IQGAP2 increases E-cadherin expression by inhibiting
AKT activation. Taken together, we demonstrate here that IQGAP2 is a candidate tumour suppressor of PC.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
IQGAP2 belongs to the IQGAP family [1,2]. The human genome
encodes three IQGAPs, IQGAP 1-3, with essentially the same domain
structure and a high level of sequence homology [2]. While human
IQGAP1 shares 62% identity to human IQGAP2 [3], both proteins have
different contributions to tumorigenesis [2]. Increase in IQGAP1 was
observed in lung cancer and oligodendroglioma [4] aswell as in colorec-
tal carcinomas [5]. At themolecular level, IQGAP1 stabilizes CDC42-GTP
via high afﬁnity interaction, thereby regulating cytoskeleton and
promoting cancer cell migration and metastasis [6–9].
IQGAP2 on the other hand inhibits tumorigenesis. Loss of IQGAP2
due to promoter methylation was detected in 55% (5/9) of gastric50Charlton Ave East, Hamilton,
fax: +1 905 521 6181.
rights reserved.cancer lines and in 47% (28/59) of primary gastric cancer [10]. Consis-
tent with IQGAP2 being predominantly expressed in the mouse liver
[3], IQGAP2 deﬁcient mice develop hepatocellular carcinoma [11] and
reduction of the IQGAP2 protein was also observed in 78% (64/82) of
human primary hepatocellular carcinomas [12]. Taken together,
evidence supports that IQGAP2 is a potential tumour suppressor.
IQGAP2 may also be involved in prostate tumorigenesis. Prostate
cancer (PC) is the most common cancer affecting men and the second
leading cause of cancer-related deaths in males in the developed
world [13,14]. The disease progresses from intra-epithelial neoplasia
or de novo, locally invasive carcinoma to metastatic cancer that
advances to hormone refractory prostate cancers (HRPCs). HRPCs con-
tribute virtually to all PC associated deaths [15,16]. While re-analysis
of existing datasets of gene expression proﬁles of prostate cancer sug-
gested increase in IQGAP2 mRNA in organ-conﬁned non-metastatic
prostate cancer [17], reduction of IQGAP2 mRNA was also reported in
hormone-refractory prostate cancer [18].
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ically examined IQGAP2 protein expression in normal prostatic glands,
PINs, early stages of PC, and advanced stages of PC. Consistentwith pub-
lications, we detected high and low levels of IQGAP2 protein in primary
prostate cancers. Although IQGAP2 was expressed at levels that were
either undetectable or low in non-tumorigenic prostate epithelial cells
and prostatic glands, its expression was signiﬁcantly increased in
androgen-dependent PC cells and early states of prostate carcinomas.
Further progression to advanced carcinomas or hormone-refractory
PC was associated with signiﬁcant reduction in IQGAP2 expression.
Furthermore, ectopic expression of IQGAP2 inhibited DU145 prostate
cancer cell invasion and serum-induced AKT activation. Taken together,
our observations strongly indicate that IQGAP2 is a surveillance type of
tumour suppressor for prostate cancer.
2. Materials and methods
2.1. Cell lines and plasmids
LNCaP, PC3, DU145, and 293 T cells were purchased from American
Type Culture Collection (ATCC), and cultured in RPMI-1640 (LNCaP),
F12 (PC3), MEM (DU145), and DMEM (293 T) plus 10% FBS and 1%
Penicillin-Streptomycin (Invitrogen). Immortalized human prostate
epithelial BPH-1 cells were kindly provided by Dr. Simon Hayward at
Vanderbilt University Medical Center, Nashville, TN, USA. BPH-1 cells
are SV40 large T antigen-immortalized human prostate epithelial cells
[19]. Human IQGAP2-EGFP cDNA was subsequently subcloned into a
retroviral vector pLPCX. E-cadherin promoter driven luciferase
construct was kindly provided by Dr. Antonio García de Herreros,
Universitat Pompeu Fabra, Spain [20].
2.2. Retroviral infection
Retroviral infectionwas performed as we have previously described
[21,22]. Brieﬂy, a gag-pol expressing vector and an envelope-expressing
vector (VSV-G) (Stratagene) were transiently co-transfected with a
designed retroviral plasmid into 293 T cells. The virus-containing
medium was harvested 48 h later, ﬁltered through a 0.45 μM ﬁlter,
and centrifuged at 20,000 g for 90 min to concentrate the retrovirus.
Polybrene (10 μg/ml, Sigma) was added before infection.
2.3. Wound healing assay and invasion assay
Wound healing assay was performed by seeding cells in triplicate in
a 6-well plate. A cross scratch (wound) was made in the middle of the
well using a 1 ml micropipette tip, when cells grew to 80–90% density.
Floating cells caused by the scratch were removed by washing cells
with PBS twice before the addition of complete cell culture medium.
The gap-closing or healing process was monitored at 2, 4, 6, 8, 12, and
24 h post scratch under a microscope equipped with a digital camera.
Gaps at three locations along a scratch were measured and averaged
for individual scratches. The gaps of three scratches from triplicates
were used to derive gap distances for individual time points of individ-
ual experiments. Experiments were repeated at least three times.
Statistical analysis was subsequently performed.
Insert chambers for 24 well plates, which contained either an 8 μm
pore size matrigel ﬁlter or a control ﬁlter, were purchased from (BD,
USA). Invasion assay was performed according to the manufacturer's
procedure. Brieﬂy, insert chambers were placed into a 24-well plate
(BD, USA) and warmed for 2 h in the presence of 0.5 ml medium.
Complete medium (0.5 ml) supplemented with 10% fetal bovine
serum (FBS) was placed in the lower chamber. 5×104 cells in 0.5 ml
serum-free medium were seeded into the top chamber and incubated
for 22 h. Cells that passed through the membranes were stained with
crystal violet (0.5%). Percentage of invasive cells was calculated by
dividing the number of cells passing through the 8 μm pore sizematrigel membrane by the number of cells migrating through the
control membrane and multiplying by 100.
2.4. Western blot analysis
Cells lysates were prepared in a buffer containing 20 mM Tris (pH
7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 25 mM
sodium pyrophosphate, 1 mM NaF, 1 mM β-glycerophosphate,
0.1 mM sodium orthovanadate, 1 mM PMSF, 2 μg/ml leupeptin and
10 μg/ml aprotinin. 50 μg of total cell lysate was separated on
SDS-PAGE gel and transferred onto Immobilon-P membranes
(Millipore).Membraneswere blockedwith 5% skimmilk and then incu-
bated with the indicated antibodies at 4°C overnight. Signals were
detected using an ECL Western Blotting Kit (Amersham). Primary anti-
bodies and concentrations used were: anti-GFP (1:500, Santa Cruz);
anti-AKT (1:1000, Santa Cruz), anti-AKT Ser473 phosphorylation
(1:1000, Cell Signaling), anti-IQGAP2 (1:200, Santa Cruz), anti-E-
cadherin (1:2500, BD), and anti-Snail (1:200, Santa Cruz).
2.5. Luciferase assay
DU145 EGFP and DU145 IQGAP2 cells were co-transfected with
pGL3 E-cadherin promoter-luciferase construct (kindly provided by
Dr. García de Herreros) and the pCH110-lacZ plasmid for 48 h.
Luciferase (Promega, USA) and β-galactosidase activity was deter-
mined. Luciferase activity was then normalized to β-galactosidase.
2.6. Immunoﬂuorescence staining
Cells were treated as deﬁned in the ﬁgure legends. Immunoﬂuores-
cence stainingwas carried out byﬁxing cells with 4% paraformaldehyde
for 20 min. Anti-IQGAP2 (1:50, Santa Cruz) and anti-E-cadherin (1:200,
BD) were then added to the slides at 4 °C overnight. After washing, sec-
ondary antibodies, FITC- or Rhodamine (TRITC)-Donkey anti-mouse IgG
(1:200, Jackson Immuno Research Lab), were applied for 1 h at room
temperature. The slide was subsequently covered with VECTASHIELD
mounting medium with DAPI (VECTOR Lab Inc., Burlingame,
CA94010). Images were taken with a ﬂuorescence microscope (Carl
Zeiss, Axiovert 200).
2.7. Knockdown of IQGAP2
Hairpin shRNAs were expressed by a retroviral-based shRNA vec-
tor (pRIH1) [21,22]. Non-speciﬁc LacZ shRNA was used as control
(Ctrl) shRNA. Speciﬁc IQGAP2 and Ctrl shRNA sequences were listed
in Supplementary Table 1. Retrovirus and infection were carried out
following our established procedure [21,22].
2.8. Collecting primary prostate cancer
Prostate tissue was collected from patients who underwent radical
prostactomy at St. Joseph's Hospital in Hamilton, Ontario, Canada
under the approval from the local Ethics Board and consent from
patients.
2.9. Immunohistochemistry (IHC)
IHC was performed on 11 parafﬁn-embedded and serially-cut pros-
tate cancer tissues obtained from St. Joseph's Hospital, Hamilton, Canada
(Supplementary Table 2). Tissue microarray (TMA) slides (BC19014
and T194) containing 42 prostate cancer patients (Supplementary
Table 3) were purchased from US Biomax. Brieﬂy, Our slides and TMA
slides were deparafﬁnized in xylene, cleared in ethanol series, and
heat-treated for 30 min in sodium citrate buffer (pH=6.0) in a food
steamer. Primary antibodies speciﬁc for IQGAP2 (1:100, Santa Cruz)
and E-cadherin (1:400, BD)were incubatedwith the sections overnight
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mouse IgG. Biotinylated goat anti-mouse IgG and Vector ABC reagent
(Vector Laboratories)were subsequently added according to themanu-
facturer's instructions. Washes were performed with PBS. Chromogen
reaction was carried out with diaminobenzidine, and counterstaining
was done with hematoxylin. Hematoxylin and eosin (H&E)
staining was carried out using a standard protocol. All spots (stained
cores) were manually examined. Semiquantitative assessment was
performed by a research fellow in a blinded fashion to evaluate the
staining intensity using a scale of 0 to 3 (0 — negative or background
staining, 1 —weak staining, 2 —modest staining, and 3 — strong stain-
ing). If an area contained patcheswith different levels of staining, values
were reported as an average of staining.
2.10. Real time PCR analysis
Total RNA was isolated using TRIZOL (invitrogen). Reverse tran-
scription was carried out using superscript III (Invitrogen, USA) accord-
ing to manufacturer's instruction. Real time PCR primers used for actin,
IQGAP2, and E-cadherin are listed in Supplementary Table 1. Real-time
PCR was performed using the ABI 7500 Fast Real-Time PCR System
(Applied-Biosystems, USA) in the presence of SYBR-green according
to the manufacturer's instructions (Applied-Biosystems, USA).
2.11. Xenograft tumor formation
DU145 monolayer (non stem cells) and sphere (stem-like) cells
were resuspended in MEM/Matrigel mixture (1:1 volume), followed
by implantation of 0.1 ml of this mixture subcutaneously (s.c.) into
ﬂanks of 8-week-old male NOD/SCID mice (The Jackson Laboratory).
Mice were inspected for tumor appearance, by observation and palpa-
tion, and tumor growth was measured weekly using a caliper. Tumor
volume was determined using the standard formula: L×W2×0.52,
where L and W are the longest and shortest diameters, respectively.
The presence of each tumor nodule was conﬁrmed by necropsy. All
animal work was carried out according to experimental protocols
approved by the McMaster University Animal Research Ethics Board.
2.12. Statistical analysis
Statistical analysis was performed using student t-test or one-way
ANOVA and pb0.05 was considered statistically signiﬁcant.
3. Results
3.1. Reduction of IQGAP2 expression in advanced prostate cancer
Loss of IQGAP2 contributes to the tumorigenesis of hepatocellular
carcinoma and gastric cancer [10–12]. The protein was detected in the
prostate of both mouse and human [23,17] and reduction of IQGAP2
mRNA was reported in advanced prostate cancer [18]. To determine
IQGAP2 protein during prostate tumorigenesis, we have examined its
expression in a panel of cell lines that reﬂect the process of prostate tu-
morigenesis, including immortalized but not transformed BPH-1
human prostate epithelial cells, androgen-dependent LNCaP as well as
androgen-independent DU145 and PC3 prostate cancer cells. While
IQGAP2was undetectable in BPH-1 cells, its expressionwas substantial-
ly increased in androgen-dependent LNCaP cells and signiﬁcantly
reduced in androgen-independent DU145 and PC3 cells (Fig. 1A). This
variation in IQGAP2 expression was at least in part due to variation in
IQGAP2 mRNA abundance based on real time PCR analysis (Fig. 1B).
Unlike the situation in gastric cancer in which promoter methylation
contributed to the reduction of IQGAP2 protein [10], promoter methyl-
ation may not play a major role in the decrease of IQGAP2 protein
observed in DU145 and PC3 cells, as 5-aza-2′-deoxtcystine (5-aza-dC),a commonly used DNA methyltransferase inhibitor, did not increase
IQGAP2 protein levels in both cell lines (data not shown).
To further evaluate the variation of IQGAP2 expression following
the progress of prostate cancer, we hve examined IQGAP2 protein in
primary prostate cancers. Low levels of IQGAP2 expression were
detected in normal prostate glands (Fig. 1C). IQGAP2 expression was
dramatically increased in prostatic intraepithelial neoplasia (PIN)
lesions and in early stages of prostate cancers that show mini-gland
structures (Gleason scores≤3) (Fig. 1C, Supplementary Fig. 1).
However, IQGAP2 expression decreased signiﬁcantly in advanced pros-
tate cancer with Gleason scores 4 and 5 (Fig. 1C). By immunohisto-
chemistry (IHC) staining of 53 primary PC tissues derived from two
independent cohorts (Supplementary Tables 2, 3), the above pattern
of IQGAP2 expression we commonly observed (Fig. 1D).
To further examine the association in the decrease in IQGAP2
following prostate cancer progression, we took advantage of our recent
demonstration that xenograft tumours derived from DU145 stem-like
cells displayed more characteristics that are associated with advanced
prostate cancer compared to xenograft tumours generated from non
stem-like DU145 cells [24]. Speciﬁcally, DU145 stem-like cells-derived
xenograft tumours were composed of 85.7±1.6% CD44+ cells versus
54.2±2.5% CD44+ cells (pb0.05) observed in xenograft tumours that
were derived from DU145 non stem-like cells [24]. The CD44+ DU145
cells are more tumorigenic compared to DU145 CD44- cells [25]. While
the xenograft tumours derived from DU145 monolayer (non stem-like)
cells expressed readily detectable membrane-bound IQGAP2 (Fig. 1E),
reduction in IQGAP2 was clearly observed in xenograft tumours that
were originated from stem-like DU145 cells (Fig. 1E). Taken together,
the above observations demonstrate that in vitro and in vivo IQGAP2
expression was dramatically up-regulated during early stages of prostate
tumorigenesis and that the levels of IQGAP2 protein were signiﬁcantly
down-regulated following PC progression to advanced stages. This
expression pattern suggests IQGAP2 being a tumour surveillance factor
that sets a barrier to prevent PC tumorigenesis.
3.2. High levels of IQGAP2 inhibit cell proliferation
To demonstrate that IQGAP2 possesses tumour suppression activi-
ties, we examined the impact of IQGAP2 on cell proliferation. When
infected with retrovirus expressing EGFP-IQGAP2, both DU145 and
PC3 cells initially displayed intensive green ﬂuorescence. Unlike EGFP-
retrovirus infected cells, these green cells could not be sustained in
the presence of antibiotic selection, suggesting that IQGAP2 might in-
hibit cell proliferation. To further investigate this possibility, DU145,
PC3, and 293 T cells were transiently transfected with EGFP or EGFP-
IQGAP2 and the number of EGFP-positive cells were followed in a peri-
od of 6 dayswithout the use of antibiotics. In comparison to EGFP cells, a
rapid decline of EGFP-positive cells was observed in PC3 and 293 T cells
transfectedwith EGFP-IQGAP2 (Fig. 2A). The trendwas also observed in
DU145 cells. However, due to relatively lower levels of transfection
(approximately 10-20% transfection rate) in DU145 cells, insufﬁcient
number of EGPF-positive cells could be recorded in randomly selected
ﬁelds under a ﬂuorescence microscope to make a meaningful quantiﬁ-
cation (data not shown). Although the difference between the EGFP
and EGFP-IQGAP2 plasmids was the presence of IQGAP2 in the latter,
we could not exclude the possibility that DU145, PC3, and 293 T cells
preferentially kicked out the EGFP-IQGAP2 plasmid. However, since
enforcing the EGFP-IQGAP retrovirus expression in these cells by the
addition of an antibiotic failed to generate stable lines expressing high
levels of EGFP-IQGAP2 (data not shown), the above observations collec-
tively indicate high levels of IQGAP2 being inhibitory to the prolifera-
tion of these cells.
Consistent with IQGAP2 being detected on the plasma membrane in
gastric cancer cells [10], ectopic IQGAP2 was largely expressed on the
plasmamembrane of DU145, PC3, and 293 T cells (Fig. 2B). Furthermore,
endogenous IQGAP2 could be detected on the plasma membrane of
Fig. 1. Differential expression of IQGAP2 during prostate tumorigenesis. (A) Cell lysates were prepared from the indicated cell lines, followed by detection of IQGAP2 and actin bywestern blot
using speciﬁc antibodies. Experimentswere repeated three times and a typical experimentwas reported. (B) Real time PCR analysis of IQGAP2 expression in the indicated cell lines.β-actinwas
used as an internal control. Data are shown as means±S.E.M. *pb0.05 by one-way ANOVA analysis. (C) IHC staining for IQGAP2 in normal prostate glands (Normal), PIN, and carcinomas.
Normal, PIN, and Gleason 3 carcinoma were from the same patient. Gleason 4 carcinoma was from a different patient. The marked regions are enlarged three fold to show details (insets).
(D) Primary prostate cancer from 11 patients (our cohort) and 42 patents (tissuemicroarray, US Biomax)were IHC stained for IQGAP2. TMA slides were scanned. Scores were given to normal
prostate glands, PIN lesions, carcinomaswithGleason scores≤3, and carcinomaswithGleason scores 4 or 5. Thenumbers of tissues involved in the analysis are indicated. *pb0.05 in comparison
to normal prostate glands or carcinomas with Gleason scores 4 or 5 (two-tailed student t-test). (E) Xenograft tumours derived from non stem-like (monolayer) or stem-like (sphere) DU145
cells were examined for IQGAP2 expression using IHC. Xenograft tumour derived from DU145 stem-like cells was also stained by Ctrl IgG. Scale bars represent 200 μm.
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LNCaP cells was more visible under the enlarged and lower-exposure
condition (Fig. 2C). More importantly, IQGAP2 was observed on the plas-
ma membrane of PIN and prostate cancer cells (Fig. 1C, Supplementary
Fig. 1). Collectively, the above observations suggest that the functional
site of IQGAP2 is on the cell membrane and the membrane-associated
IQGAP2 inhibits prostate cancer cell proliferation. The observation that
endogenous IQGAP2 in DU145 cells is not readily detectable on the cellsurface is consistent with our model that loss of IQGAP2 function plays
a role in prostate cancer progression (see Discussion for details).3.3. IQGAP2 reduces DU145 cell invasion
While we were unable to construct a DU145 cell line that stably ex-
presses a high level of ectopic IQGAP2 (data not shown), we generated
Fig. 2. IQGAP2 inhibits prostate cancer cell proliferation. (A) 293 T (left panel) and PC3 (right panel) were transfected with pLPCX EGFP or pLPCX EGFP-IQGAP2 constructs. Cells in
four randomly selected ﬁelds were counted every day under both visible and ﬂuorescence wave lengths. Approximately 600–1000 cells were counted daily and the percentages of
EGFP-positive cells were calculated and graphed. *pb0.05 (two-tailed student t-test). (B) DU145, PC3, and 293 T cells were transiently transfected with EGFP or EGFP-IQGAP2
(IQGAP2) constructs. Typical ﬂuorescence images at day 2 of post-transfection are shown. The marked cells are enlarged 5 folds and presented underneath of the respective images.
Scale bars represent 50 μm. (C) DU145 and LNCaP cells were immunoﬂuorescence stained for IQGAP2. 0.05% Saponin (Sigma, USA ) instead of Triton X-100 was used to preserve cell
membrane-associated IQGAP2. Scale bars represent 5 μm. The marked LNCaP cell was enlarged 2 folds and exposure was also reduced to show IQGAP2 membrane localization.
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EGFP-IQGAP2 fusion protein was detected by an anti-GFP antibody,
which runs at a higher molecular weight than the endogenous
IQGAP2 (Fig. 3A). The ectopic protein was expressed at a comparable
level as the endogenous IQGAP2 (Fig. 3A, middle panel), an observation
consistent with our previous ﬁndings that DU145 cells were unable to
support high levels of ectopic IQGAP2 due to its inhibitory effects on
cell proliferation. In accordance with this notion, this low level of
EGFP-IQGAP2 was not sufﬁcient to reduce cell proliferation. When
cultured at low densities, ranging from 50, 100, and 1000 cells/well
in a 6-well plate, comparable number and size of colonies were formed
during 2 weeks between DU145 EGFP and DU145 EGFP-IQGAP2 cells(Supplementary Fig. 2). Taken together, the above observations reveal
that ectopic EGFP-IQGAP2, when expressed at the level comparable to
that of endogenous IQGAP2, does not affect the cells’ surviving and
proliferation ability.
We subsequently determined whether ectopic EGFP-IQGAP2 affects
DU145 cells' ability to grow in soft agar. In comparison to DU145 EGFP
cells, DU145 EGFP-IQGAP2 cells formed comparable numbers and
sizes of soft agar colonies (data not shown), suggesting that ectopic
EGFP-IQGAP2 had no effect on DU145 cells’ ability to grow in an
anchorage-independent manner.
As cancer cell's ability to metastasis in vivo correlates with cell's
migration and invasion potentials, we have investigated the impact of
Fig. 3. IQGAP2 inhibits DU145 cell invasion. (A) DU145 cells were stably infected with retrovirus expressing either EGFP or EGFP-IQGAP2 fusion protein. Expression of EGFP was
conﬁrmed (data not shown). Ectopic EGFP-IQGAP2 fusion protein was detected by western blot using anti-EGFP antibody (top panel) and anti-IQGAP2 antibody (middle panel).
The location of endogenous IQGAP2 (IQGAP2) is indicated. (B), (C) DU145 EGFP and DU145 IQGAP2 (EGFP-IQGAP2) cells were examined for their ability to pass through a control
and matrigel membrane. Experiments were carried out at least three times. Typical images from one experiment are shown (B) and quantiﬁcation data are also presented as
means±S.E.M. (*pb0.05, two-tailed student t-test) (C). (D), (E), (F) Experiments similar to those described in panels A–C were also carried out in DU145 cells infected with
retrovirus expressing a control (Ctrl) shRNA or IQGAP2 shRNA.
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EGFP cells closed gaps marginally faster than DU145 EGFP-IQGAP2
cells (data not shown). However, in comparison with DU145 EGFP
cells DU145 EGFP-IQGAP2 cells passed through (invade) a matrigel-
membrane with signiﬁcantly reduced efﬁciency (Fig. 3B, C). Conversely,
knockdown of IQGAP2 enhanced DU145 cell's invasion ability
(Fig. 3D–F). Collectively, the above observations demonstrate that
IQGAP2 reduces DU145 cells' invasion potential.3.4. IQGAP2 inhibits EMT and attenuates growth-factors induced
AKT activation
Epithelial-mesenchymal transition (EMT) is an essential process of
metastasis [26,27]. The observation that IQGAP2 inhibited DU145 cell
invasion suggested that it may reduce EMT. As loss of E-cadherin is
the hallmark of EMT, we were able to show that IQGAP2 increases
E-cadherin expression. Ectopic expression of IQGAP2 up-regulated
E-cadherin in DU145 cells (Fig, 4A) and PC3 cells (Supplementary
Fig. 3A). This was at least in part attributable to the increase in transac-
tivation of the E-cadherin gene (Fig. 4B, Supplementary Fig. 3A).
Consistent with loss of E-cadherin being a major surrogate marker of
EMT, ectopic overexpression of IQGAP2 reduced ﬁbronectin expression,
a well knowmesenchymal marker (Fig. 4C). As E-cadherin inhibits can-
cer cells invasion bymediating cell-cell adhesion, wewere able to show
that in comparison to DU145 EGFP cells, DU145 EGFP-IQGAP2 cells dis-
played more membrane-bound E-cadherin (Fig. 4D). Additionally, in
comparison with DU145 EGFP cells, DU145 EGFP-IQGAP2 cells prolifer-
ated as adhesive cell “sheets” (Fig. 4E). Morphologically DU145 EGFP
cells are more mesenchymal-like, while DU145 EGFP-IQGAP2 cells dis-
play more epithelial characteristics (Fig. 4E). Furthermore, knockdownof IQGAP2 in DU145 cells (Fig. 3D) resulted in the reduction of
E-cadherin (Fig. 4F). Taken together, the above observations demon-
strate that IQGAP2 functionally regulates E-cadherin expression.
To further consolidate this notion, we observed that while the levels
of IQGAP2 follow the order of LNCaP>DU145>PC3 (Fig. 1A), the levels
of E-cadherin are in the same order in these lines (Fig. 5A). BPH-1 cells
are immortalized but non tumorigenic human prostate epithelial cells
[19]. These cells express high levels of E-cadherin (Fig. 5A) without
expressing detectable IQGAP2 (Fig. 1A), which is consistent with the ob-
served low levels of IQGAP2 in prostate gland (Fig. 1C). While IQGAP2
levels correlated with E-cadherin expression in cultured prostate cancer
cells, IQGAP2 partially correlates with E-cadherin expression in DU145
cells-derived xenograft tumours (Fig. 5B) and in primary prostate carci-
nomas (Fig. 5C). While IQGAP2-positive cells are generally E-cadherin
positive in xenograft tumours (Fig. 5B, see rectangular marked regions)
and in primary PC (Fig. 5C), there are clearly cells that express low levels
of IQGAP2 but high levels of E-cadherin in xenograft tumours (Fig. 5B,
circular areas) and in primary tumours (Fig. 5C, asterisks-labelled can-
cers). These observations suggest that IQGAP2 is not the sole regulator
of E-Cadherin. Furthermore, consistent with the previous discussions
(Fig. 1C, Supplementary Fig. 1), IQGAP2 was largely expressed on the
cell membrane in both xenograft and primary prostate cancer
(Fig. 5B, C). Taken together, the above observations support the notion
that IQGAP2 contributes to E-cadherin expression.3.5. IQGAP2 upregulates E-cadherin by inhibiting AKT activation
We subsequently determined the underlying mechanisms responsi-
ble for IQGAP2-mediated E-cadherin expression. As IQGAP2 enhanced
E-cadherin promoter activity (Fig. 4B, Supplementary Fig. 3B), we ﬁrst
Fig. 4. IQGAP2 upregulates E-cadherin. (A) Western blot analysis of E-cadherin and actin in DU145 EGFP (EGFP) and DU145 EGFP-IQGAP2 (IQGAP2) cells. (B) DU145 EGFP and DU145
IQGAP2 (EGFP-IQGAP2) cells were transiently transfectedwith an E-cadherin promoter driven luciferase and a CMV driven lacZ construct for 48 h, followed by assaying for luciferase and
β-Gal activities. Luciferase activity was normalized to β-Gal activities and expressed as fold changes to luciferase activity in DU145 EGFP cells. Data from three independent repeats are
reported as means±S.E.M. (*pb0.05, two-tailed student t-test). (C), (D) Immunoﬂuorescence staining of ﬁbronectin and E-cadherin in DU145 EGFP and DU145 IQGAP2 (EGFP-IQGAP2)
cells. Nuclei were counter stained with DAPI (blue). Merged images of ﬁbronectin or E-cadherin (red) and nucleus (blue) are also provided. (E) DU145 EGFP and DU145 IQGAP2 (EGFP-
IQGAP2) cellswere seeded at the same density. Phase contrast imageswere taken 2 days later. Scale bars represent 200 μm. (F)Western blot analysis of E-cadherin and actin inDU145 Ctrl
shRNA and DU145 IQGAP2 shRNA cells.
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tion repressors. These repressors include Snail, Twist, ZEB1, SIP1, and
E12/E47 with Snail being the most important one [28,29]. While overex-
pression of IQGAP2 increased E-cadherin expression (Fig. 4A), ectopic
IQGAP2 did not decrease Snail expression in DU145 cells (data not
shown), indicating that Snail is not the major contributor to IQGAP2-
mediated up-regulation of E-cadherin. As the PI3K-AKT pathway plays
amajor role in promoting cancermetastasis and because AKT contributes
to loss of E-cadherin [30–32], we have examined whether IQGAP2 may
regulate E-cadherin expression via affecting AKT activation. While fetal
bovine serum (FBS) dose-dependently stimulated AKT activation in
DU145 EGFP cells with the plateau induced by 3-5% FBS, serum induced
much lower levels of AKT activation in DU145 EGFP-IQGAP2 cells with a
slower kinetics (Fig. 6A, B).To examine whether reduction in AKT activation contributes to
IQGAP2-mediated increases of E-cadherin, we have treated DU145
cells with increasing doses of an AKT inhibitor (AKT inhibitor VIII).
While the inhibitor decreased AKT activation, as expected (Fig. 6C), it
also increased E-cadherin expression (Fig. 6C). Taken together, our
observations demonstrated that IQGAP2 upregulates E-cadherin by, at
least in part, inhibiting AKT activation.
4. Discussion
IQGAP2 has been shown to possess tumour suppressor functions
largely owing to the observed reduction of IQGAP2 in primary human
gastric cancer and hepatocellular carcinoma (HCC) as well as the ﬁnd-
ing that IQGAP2 deﬁciency contributed to HCC tumorigenesis in mice
Fig. 5. IQGAP2 expression correlateswith E-cadherin expression in prostate cancer. (A)Western blot analysis of E-cadherin and actin in non-tumorigenic humanBPH-1 prostate epithelial
cells, androgen-dependent LNCaP and androgen-independent DU145 and PC3 cells. (B) DU145 cells-derived xenograft tumors were generated in NOD/SCID mice and examined for
IQGAP2 and E-cadherin expression. The areas marked with rectangular shapes are for regions positive for both IQGAP2 and E-cadherin. The circular regions express low levels of
IQGAP2 but high levels of E-cadherin. Scale bars represent 200 μm. (C) IQGAP2 and E-cadherin from two individual patients with Gleason 3 carcinomas were examined by IHC. The
asterisks represent the same tumor expressing low levels of IQGAP2 but high levels of E-cadherin. Scale bars represent 100 μm.
882 Y. Xie et al. / Biochimica et Biophysica Acta 1822 (2012) 875–884[10–12]. While IQGAP2 is predominantly expressed in the liver [3], its
expression was detected in other tissues [2], including prostate [23],
suggesting that IQGAP2 may also play a role in the suppression of
prostate tumorigenesis.
We provide evidence that IQGAP2 is a potential tumour suppressor
of prostate cancer. During the process of prostate tumorigenesis,
IQGAP2 protein levels displayed a two-phase change.While in cultured
cells IQGAP2 was expressed at an undetectable or low level in non-
tumorigenic BPH-1 prostate epithelial cells, its expression was sharply
increased in androgen-dependent LNCaP cells and then signiﬁcantly
decreased in androgen-independent PC cells, DU145 and PC3 cells.
Furthermore, evidence suggests that IQGAP2 suppresses gastric cancer
tumorigenesis via its cell membrane localization [10].We also observed
membrane localization of IQGAP2 in PIN lesions and in early stages of
prostate cancer. Additionally, ectopic IQGAP2 inhibited DU145 and
PC3 cell proliferation and ectopic IQGAP2 was clearly detected on the
cellmembrane. Collectively, evidence exists that suggests the functional
site of IQGAP2 in the suppression of prostate tumorigenesis being at the
cell membrane. It is thus intriguing to notice that IQGAP2was not read-
ily observed on the membrane of DU145 cells (Fig. 2C), suggesting that
in addition to the decrease of IQGAP2, its function may also be compro-
mised in DU145 cells. However, it is also possible that the low level of
IQGAP2 in these cells made the detection of membrane-associated
IQGAP2 difﬁcult. Nonetheless, the concept of reduction of IQGAP2 func-
tion in advanced prostate cancer is in line with the notion that IQGAP2
inhibits prostate cancer progression.
The bi-phase change in IQGAP2 protein observed in cultured pros-
tate cancer cells was recapitulated in primary prostate cancer tissues.
In comparison to prostate gland epithelial cells, IQGAP2 expression
was signiﬁcantly increased in pre-cancerous PIN lesions and in early
stage prostate cancers with Gleason scores 3, which was followed by asigniﬁcant decrease in advanced prostate carcinomas with Gleason
score 4 or 5. Our results are consistent with recent reports showing
high and low levels of IQGAP2 mRNA were detected in organ-
conﬁned and in hormone-refractory prostate cancers, respectively
[17,18]. This pattern of expression closely matches the expression pat-
tern of the tumour surveillance type of tumour suppressors, p14ARF
[33]. It is thus tempting to propose that IQGAP2 may suppress prostate
cancer tumorigenesis by the surveillance of oncogenic activities. Typical
oncogenic events of prostate cancer include the EST fusion genes
[34,35], abnormal androgen signalling [36], and activation of the PI3K-
ATK pathway [37]. When such activities reach a threshold, IQGAP2 is
elevated to prevent tumorigenesis. Reduction of IQGAP2 is thus needed
for prostate cancer progression to advance. Consistent with this notion,
we found that IQGAP2 up-regulates E-cadherin via inhibiting AKT acti-
vation. Therefore, it will be interesting to examine whether loss of
IQGAP2 promotes prostate tumorigenesis and progression in prostate-
speciﬁc PTEN knockout mice [38].
While it is likely that reduction of IQGAP2 is not the onlymechanism
promoting prostate cancer progression, the concept of IQGAP2 being a
surveillance type of tumour suppressor for prostate cancer is very in-
triguing. Importantly, this concept is supported by our ﬁndings that
IQGAP2 inhibited prostate cancer proliferation and invasion.
While promoter methylation contributes largely to the decrease in
IQGAP2 in gastric cancer [10], this is not the major cause for reduction
of IQGAP2 mRNA in HCC [12]. As 5-aza-dc did not increase IQGAP2
protein expression in both DU145 and PC3 cells (data not shown),
reduction of IQGAP2 mRNA in advanced prostate cancer may not be
attributable to promoter methylation, a situation similar to that
observed in HCC. IQGAP1 and IQGAP2 were reported to be regulated
in a reversed manner in human tumours [39,12] and IQGAP1 is inhib-
ited by tumour suppressing microRNA, miR-124 [40,41]. It is therefore
Fig. 6. IQGAP2 reduces AKT activation. DU145 EGFP and DU145 IQGAP2 (EGFP-IQGAP2)
cells were serum starved overnight and then stimulated with the indicated doses of FBS
for 30 min. Typical western blot images of AKT activation (phosphorylation at S473,
p-AKT) and total AKT from one experiment are shown (A). Data from three independent
experiments are graphed as means±S.E.M. (*pb0.05) (two-tailed student t-test) (B).
(C) DU145 cells were either mock-treated (DMSO) or treated with an AKT inhibitor
(AKT inhibitor VIII, Calbiochem, USA) for overnight at the indicated doses, followed by
examination for E-cadherin, pAKT, AKT, and actin by western blot.
883Y. Xie et al. / Biochimica et Biophysica Acta 1822 (2012) 875–884possible thatmiR-124 or other types ofmicroRNAmay regulate IQGAP2
expression in prostate cancer.
Prior to our research, IQGAP2 has been shown to be a potential tu-
mour suppressor for gastric cancer and HCC [10–12]. However, the un-
derlying mechanisms governing IQGAP2-mediated tumour suppressor
remain elusive. While IQGAP1 stabilizes CDC42-GTP complex via high
afﬁnity association with the complex, the impact of IQGAP2 on CDC42
signalling is unclear. This is because IQGAP2 interacts with both GTP-
and GDP-bound CDC42 [42,43]. Despite having 62% identity [3], both
proteins not only express disparately in cancers [39,11] but also func-
tion oppositely in tumorigenesis [2]. IQGAP1 has been demonstrated
to bind E-cadherin and inhibited E-cadherin-mediated cell-cell adhe-
sion [44]. Whether IQGAP2 also affects E-cadherin in an opposite direc-
tion i.e. facilitating E-cadherin-mediated cell-cell adhesion remained
unknown. In line with the theme that IQGAP2 works in the opposite
direction from IQGAP1 in tumorigenesis, we provide evidence that
IQGAP2 robustly up-regulated E-cadherin in both DU145 and PC3
cells (Fig. 4A, B; Supplementary Fig. 3). Ectopic overexpression of
IQGAP2 resulted in DU145 cells assumingmore epithelial cell morphol-
ogy (Fig. 4E) with decrease in a mesenchymal marker ﬁbronectin
(Fig. 4C), indicating that IQGAP2 functionally enhances E-cadherin
expression and reduces EMT. Unlike IQGAP1, IQGAP2 does not
co-localize with E-cadherin (Supplementary Fig. 4), indicating that
IQGAP2 does not bind E-cadherin. Our ﬁndings that IQGAP2 functional-
ly enhances E-cadherin expression are consistent with recentpublications. Knockdown of IQGAP2 disrupted cadherin-mediated
cell-cell adhesion in Xenopus laevis embryos [45] and IQGAP2 deﬁcient
mice showed the loss ofmembrane E-cadherin in hepatocytes [11]. Fur-
thermore, our observation that IQGAP2 inhibits prostate cancer pro-
gression via upregulation of E-cadherin is consistent with the concept
that EMT plays a role in promoting prostate cancer progression [46].
While how IQGAP2 upregulates E-cadherin expression requires fur-
ther investigation, the PI3K-AKT pathway in part contributes to this
process. IQGAP2 was found to reduce serum-induced AKT activation
and AKT activity inhibits E-cadherin expression. While IQGAP2 may
promote E-cadherin expression via inhibiting AKT activation, down-
regulation of AKT activation may also be involved in other aspects of
IQGAP2-mediated tumour suppression. Collectively, IQGAP2's actions
in the increase of E-cadherin and decrease in AKT activation contribute
at least in part to its tumour suppression activity. Although how IQGAP2
reduces AKT activation remains unclear, based on the predominant
membrane localization of IQGAP2, it is plausible that IQGAP2 may re-
duce the accumulation of phosphatidylinositol 3,4,5-triphosphate
(PIP3), the recruitment of AKT to the plasma membrane, or the activa-
tion of AKT at the plasma membrane.
Interestingly, the above discussions are in line with the theme that
IQGAP2 may function in a manner opposite to IQGAP1 [11,39,12].
IQGAP1 has been recently demonstrated to promote AKT activation in
hepatocellular carcinoma [47]. Additionally, IQGAP1 was well docu-
mented to promote tumour cell migration and invasion [48–51]. Both
IQGAP1 and IQGAP2 have 62% of overall identity [3]. More importantly,
both proteins share even higher levels of homology in their conserved
structural motifs, except the poly-proline protein-protein domain [2].
Therefore, it remains to be determined what are the unique structural
elements contributing to their opposite functions in regulating a variety
of signalling events.
Supplementary materials related to this article can be found online
at doi:10.1016/j.bbadis.2012.02.019
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